E-mail this page Printer Friendly Version RSS E-mail Alerts View contacts Download Financial Tear Sheet 

2011 Press Releases

This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007
DateTitle 
12/09/11Quest Diagnostics Care360™ Named Top e-Prescribing Platform by Black Book Rankings
- Care360™ Ranked #1 in Customer Experience and Satisfaction - More than 92 Percent of Care360™ Clients Are On Track for Meaningful Use MADISON, N.J., Dec. 9, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that Care360™, the company's electronic health platform, has been named the leading stand-alone e-Prescribing software system by Black Book Rankings, a leading sou... 
Printer Friendly Version
12/08/11One in Three First-Time Participants in Laboratory-Based Wellness Program Learn of High Risk for Chronic Disease, Quest Diagnostics Study Shows
Eighty-Nine Percent of Those at High Risk for Chronic Kidney Disease, 59 Percent of Those at High Risk for High Cholesterol, and 28 Percent of Those at High Risk for Diabetes First Learned of Health Condition through Lab-Based Wellness Program MADISON, N.J., Dec. 8, 2011 /PRNewswire/ -- One in three first-time participants in a company-sponsored, lab-based wellness program were not aware they were at high risk for a serious medical condition, according to an article publis... 
Printer Friendly Version
12/07/11Quest Diagnostics Adds Timothy M. Ring to Board of Directors
MADISON, N.J., Dec. 7, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors has elected Timothy M. Ring to serve as a director, effective immediately. Including Mr. Ring, the Board has nine members. Mr. Ring is Chairman and Chief Executive Officer of C. R. Bard, Inc., a leading multinational developer, manufacturer and marketer of innovative, life-e... 
Printer Friendly Version
12/06/11Quest Diagnostics Launches Simplexa™ Dengue Test in Brazil, First Commercial Molecular Test Approved for Nation's Public and Private Health Testing
Country's public health labs now evaluating the test's potential for aiding clinical management of the country's nearly one million Dengue fever cases MADISON, N.J. and CYPRESS, Calif., Dec. 6, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa™ Dengue molecular test kit developed by its Focus Diagnostics products business has been registered for distribution in Braz... 
Printer Friendly Version
11/15/11Quest Diagnostics CE Marks Simplexa(TM) Test for Cytomegalovirus for Sale in Europe
With the new Focus Diagnostics' Simplexa molecular test on the 3M(TM) Integrated Cycler, the company now offers one of the most comprehensive molecular transplant-testing menus in Europe MADISON, N.J. and CYPRESS, Calif., Nov. 15, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Focus Diagnostics business has CE marked its new Simplexa Cytomegalovirus (CMV) molecular test k... 
Printer Friendly Version
11/11/11Quest Diagnostics to Speak at the Lazard Capital Markets 8th Annual Healthcare Conference
MADISON, N.J., Nov. 11, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Lazard Capital Markets 8th Annual Healthcare Conference in New York City.  The presentation is scheduled for Tuesday, November 15, 2011 at 11:30 a.m. Eastern Time. During the conference, the company will reaffirm its 2011 outlook before future special items. The company expects re... 
Printer Friendly Version
11/08/11Quest Diagnostics Encourages Denver Area Residents to Enroll in Historic American Cancer Society Prevention Study November 8th - 19th
Company Applauds American Cancer Society for Working to Inform the Fight Against Cancer for Future Generations DENVER, Nov. 8, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics joined the American Cancer Society today to encourage Denver-area residents to participate in the American Cancer Society's historic Cancer Prevention Study - 3 (CPS-3). The Denver enrollment period for this national, longitudinal study is between November 8 and 19, 2011. The CPS-3 Study focuses on uncovering the lifes... 
Printer Friendly Version
11/01/11Quest Diagnostics Announces Launch of Simplexa(TM) Direct Test for Influenza and Respiratory Viruses in Europe
Focus Diagnostics product eliminates nucleic-acid sample extraction with proprietary technology, for faster testing CYPRESS, Calif. and MADISON, N.J., Nov. 1, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the CE mark and European availability of the Simplexa Flu A/B & RSV Direct test on the 3M(TM) Integrated Cycler. The new test, from the company's Focus Diagnostics ... 
Printer Friendly Version
10/25/11Quest Diagnostics Reports Third Quarter 2011 Financial Results
-- Revenues of $1.9 billion, up 2.2% -- Adjusted diluted EPS of $1.18, up 4%; reported diluted EPS of $1.08, down 4% -- Cash flow from operations of $338 million, up $8 million -- Quarterly dividend increased by 70% to $0.17 per share MADISON, N.J., Oct. 25, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that for the third quarter ended September 30, 2011, adjusted income from co... 
Printer Friendly Version
10/25/11Quest Diagnostics Increases Quarterly Cash Dividend
MADISON, N.J., Oct. 25, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors has increased the quarterly cash dividend to $0.17 per share, payable on January 24, 2012, to shareholders of record of Quest Diagnostics common stock on January 9, 2012. The dividend represents a 70% increase from the current $0.10 per share level. "This increase in our di... 
Printer Friendly Version
10/25/11Quest Diagnostics Initiates CEO Succession Process
Surya Mohapatra to Remain Chairman and CEO to Ensure Smooth Transition -- MADISON, N.J., Oct. 25, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX) today announced that its Board of Directors has begun the process of identifying a successor to Surya N. Mohapatra, Ph.D., President, Chairman and Chief Executive Officer. The Board of Directors has formed a search committee, engaged a leading executive recruitment firm and will consider both external and internal candida... 
Printer Friendly Version
10/13/11Quest Diagnostics to Release Third Quarter 2011 Financial Results
MADISON, N.J., Oct. 13, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report third quarter 2011 results on Tuesday, October 25, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the conference call through a live audio webcast available on Qu... 
Printer Friendly Version
10/11/11Hydrocodone and Oxycodones Lead U.S. General Workforce Positives, Outranked Only by Marijuana, According to Quest Diagnostics Drug Testing Index(TM)
Hydrocodone and oxycodones remain most detected prescription opiates in U.S. general workforce Random drug tests for hydrocodone and oxycodones find nearly double the positives than pre-employment screening MADISON, N.J., Oct. 11, 2011 /PRNewswire via COMTEX/ --American workers continue to use prescription opiates at relatively high levels, according to Drug Testing Index(TM) (DTI) data released today by Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic t... 
Printer Friendly Version
09/27/11Quest Diagnostics Named Healthiest Employer in Philadelphia, Baltimore and Washington, D.C. Regions
Regional honors follow company's Platinum-Level 'Best Employer for Healthy Lifestyles' distinction from National Business Group on Health MADISON, N.J., Sept. 27, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services has been ranked as top healthy employer in the Philadelphia, Baltimore and Washington, D.C. regions. These honors follow the company's selection in May as a Platinum-level 'Best Employer for Heal... 
Printer Friendly Version
09/13/11New Rules Opening Access to Lab Test Results Will Empower Patients to Understand Their Health Better
MADISON, N.J., Sept. 13, 2011 /PRNewswire via COMTEX/ --New rules proposed by the U.S. Department of Health and Human Services (HHS) to expand the rights of Americans to access their personal health information will empower patients to understand their health condition better, according to Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostics testing, information and services. "Patient engagement in healthcare decision making is vital to promoting better health outcomes... 
Printer Friendly Version
09/09/11Quest Diagnostics Selected as Member of Dow Jones® Sustainability Index
Company Again Named to Both World and North American Indexes MADISON, N.J., Sept. 9, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that it has again been selected to be part of the Dow Jones® Sustainability World Indexes and North America Indexes (DJSI World and DJSI North America). "Quest Diagnostics is proud to be included in the Dow Jones Sustainability Index," sa... 
Printer Friendly Version
09/08/11Quest Diagnostics to Speak at the Morgan Stanley Global Healthcare Conference
MADISON, N.J., Sept. 8, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York City. The presentation is scheduled for Tuesday, September 13, 2011 at 10:55 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the follow... 
Printer Friendly Version
09/02/11Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index(TM)
Five-year data suggest methamphetamine's national decline has halted and that the drug's stronghold may be moving eastward MADISON, N.J., Sept. 2, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today issued its annual report on U.S. worker drug use, the Quest Diagnostics Drug Testing Index(TM). The study includes its first state-by-state analysis of methamphetamine positives, based on mor... 
Printer Friendly Version
08/12/11Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Aug. 12, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on October 24, 2011, to shareholders of record of Quest Diagnostics common stock on October 7, 2011. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information ... 
Printer Friendly Version
07/25/11Quest Diagnostics to Unveil Extensions to its Women's Health and Personalized Medicine Test Offerings at the 2011 AACC Annual Meeting and Clinical Lab Expo
Athena Diagnostics' spinal muscular atrophy (SMA) testing menu is broadly available nationally to Quest Diagnostics' clients for the first time Quest Diagnostics will also present novel scientific research and host the "What's New in Laboratory Medicine?" scientific speaker series in booth 3130 MADISON, N.J., July 25, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced it will... 
Printer Friendly Version
07/20/11Quest Diagnostics Reports Second Quarter 2011 Financial Results
-- Revenues of $1.9 billion, up 1.5% -- Adjusted diluted EPS of $1.12, up 5%; reported diluted EPS of $1.02, down 5% -- Updated 2011 adjusted guidance before special items: Diluted EPS between $4.25 and $4.35; revenues to grow 1.5% -- New initiative to reduce cost structure by $500 million and position company for the future MADISON, N.J., July 20, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and ... 
Printer Friendly Version
07/14/11Quest Diagnostics and Genomic Vision Form Strategic Collaboration to Develop Genome-based Laboratory Tests
Genomic Vision's Molecular Combing genomic-analysis technique to provide basis for developing new clinical testing services for cancer, neurology and other diseases MADISON, N.J. and PARIS, July 14, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, and Genomic Vision, a biotechnology company dedicated to the development of molecular diagnostics, today announced a multi-year exclusive collaboration involv... 
Printer Friendly Version
07/06/11Quest Diagnostics to Release Second Quarter 2011 Financial Results
MADISON, N.J., July 6, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report second-quarter 2011 results on Wednesday, July 20, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the conference call through a live audio webcast available on Que... 
Printer Friendly Version
06/27/11Poll: One in Three Adults 60-70 Years of Age Screened for Colon Cancer Have Only Done So Once, Suggesting Failure to Follow Periodic Testing Guidelines
Poll also finds while most screened opt for colonoscopy, those who do not cite unpleasant bowel preparation and side effects as the chief reasons they prefer a different colon cancer test WASHINGTON, June 27, 2011 /PRNewswire via COMTEX/ -- Results from a nationwide research poll released today by the Colon Cancer Alliance and Quest Diagnostics (NYSE: DGX) suggest that one in three of men and women age 60-70 who have been screened for colon cancer have done so only once, suggesting a failure t... 
Printer Friendly Version
06/22/11Quest Diagnostics Gazelle® Mobile Health Platform Now Available for Android Smartphones
MADISON, N.J., June 22, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced a new version of Gazelle, the company's mobile health platform, which now features compatibility with the fast-growing Google Android® smartphone operating system. (Photo: http://photos.prnewswire.com/prnh/20110622/NY24398) Gazelle for Android is now available for download free of charge at Gazelleapp.com and in... 
Printer Friendly Version
06/16/11Nearly One in Three Men and Women Age 50 and Over Have Not Been Screened for Colon Cancer; One in Four Say their Healthcare Provider Didn't Recommend Screening
Poll respondents also report "too busy" and "fear" as reasons they haven't been screened, but most claim they would be screened if a blood test were available WASHINGTON, June 16, 2011 /PRNewswire via COMTEX/ --Results from a nationwide research poll released today by the Colon Cancer Alliance and Quest Diagnostics (NYSE: DGX) show that 31 percent of men and women age 50 years and over have never been screened for colon cancer by standard screening methods such as a colonoscopy, fecal occult ... 
Printer Friendly Version
06/09/11Quest Diagnostics Wins Gold Medical Design Excellence Award (MDEA) for Diagnostic Innovation
Focus Diagnostics Simplexa(TM) molecular test on the 3M(TM) Integrated Cycler Wins Highest MDEA Award for in vitro diagnostics MADISON, N.J., June 9, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Simplexa(TM) molecular diagnostic test on the 3M(TM) Integrated Cycler won a gold award in the in vitro diagnostics category at the 2011 MDEA awards ceremony yesterday i... 
Printer Friendly Version
06/03/11Quest Diagnostics to Speak at the Jefferies 2011 Global Healthcare Conference
MADISON, N.J., June 3, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Jefferies 2011 Global Healthcare Conference in New York City. The presentation is scheduled for Monday, June 6, 2011 at 8:30 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following site:... 
Printer Friendly Version
05/25/11Men May Have Greater Allergy Risk Than Women, Suggests Largest Ever National Allergy Study
Quest Diagnostics Health Trends analysis raises possibility that men are underdiagnosed for allergies MADISON, N.J., May 25, 2011 /PRNewswire via COMTEX/ -- A study of nearly 14 million blood tests for aiding allergy diagnosis shows that men exhibited higher sensitivity to 11 common allergens than women when tested, contradicting other research suggesting women experience allergies more frequently than men. The study's findings raise the possibility that men have a higher risk for allergies t... 
Printer Friendly Version
05/24/11OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment
Second study in Obstetrics & Gynecology showcases OVA1's role in evaluating women with an ovarian mass MADISON, N.J. and AUSTIN, Texas, May 24, 2011 /PRNewswire via COMTEX/ -- A paper published in the June issue of Obstetrics & Gynecology demonstrated that adding OVA1 to a physician's preoperative assessment of a woman's ovarian mass would identify more ovarian cancers than a physician's preoperative assessment alone. The study is the second published online this month in the journal, ... 
Printer Friendly Version
05/24/11Quest Diagnostics Earns Platinum Honor as "Best Employer for Healthy Lifestyles" for Third Consecutive Year
National Business Group on Health Recognizes HealthyQuest Program for Seventh Straight Year WASHINGTON, and MADISON, N.J., May 24, 2011 /PRNewswire/ -- The National Business Group on Health (NBGH) has awarded its 2011 Best Employers for Healthy Lifestyles Platinum Award to Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services. The 2011 award, in recognition of the company's HealthyQuest employee wellness initiative, marks the ... 
Printer Friendly Version
05/23/11Ragweed and Mold Lead Overall Upswing in Allergy Prevalence; Climate Change Suspected
Quest Diagnostics Health Trends analysis of nearly 14 million allergy tests ranks "30 Worst Big Cities for Ragweed" (Click here for ranking) MADISON, N.J., May 23, 2011 /PRNewswire via COMTEX/ -- Early results from the largest cross-sectional national allergy study ever conducted, to be released later this week, suggest that allergies have increased in America, but that most of the increase was due to two environmental allergens, ragweed and mold. The study, based on nearly 14 million test res... 
Printer Friendly Version
05/19/11Quest Diagnostics Finalizes Agreement to Settle California Lawsuit Related to Medi-Cal Billing
MADISON, N.J., May 19, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX) today announced it has finalized an agreement to settle a previously disclosed civil lawsuit, brought by a California competitor against a number of California clinical laboratories, in which the State of California intervened, for a payment of $241 million. The company had announced an agreement in principle to resolve the lawsuit on May 9, 2011. In the lawsuit, the plaintiffs alleged, among other t... 
Printer Friendly Version
05/17/11Quest Diagnostics Successfully Completes Acquisition of Celera
MADISON, N.J., May 17, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the successful completion of its acquisition of Celera Corporation (NASDAQ: CRA). The acquisition was completed by means of a short-form merger under Delaware law, under which a wholly owned subsidiary of Quest Diagnostics was merged with and into Celera, with Celera surviving the merger as a wholly owned ... 
Printer Friendly Version
05/17/11Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., May 17, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on July 19, 2011, to shareholders of record of Quest Diagnostics common stock on July 5, 2011. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information and ser... 
Printer Friendly Version
05/17/11Food Allergies Common among Children and Linked to Environmental Allergies and Asthma Later in Life, Suggests Largest-Ever National Allergy Study
Quest Diagnostics Health Trends(TM) Report also finds economically disadvantaged children tested for allergies at later ages MADISON, N.J., May 17, 2011 /PRNewswire via COMTEX/ -- Early results from the largest cross-sectional national allergy study ever conducted, to be released later this month, demonstrate that food allergies commonly occur in infants and toddlers, while environmental allergies, such as to dust, ragweed and mold, are more common in older children and adults. The study, bas... 
Printer Friendly Version
05/12/11OVA1 Blood Test Detects Ovarian Cancer More Accurately Than Medically Accepted CA 125 Method for Evaluating Women with Ovarian Mass
Obstetrics & Gynecology study also considers OVA1's place in future surgical referral guidelines MADISON, N.J. and AUSTIN, Texas, May 12, 2011 /PRNewswire via COMTEX/ -- A study published online ahead of print in the June 2011 edition of Obstetrics & Gynecology demonstrated that American College of Obstetrics and Gynecology (ACOG) guidelines for determining the likelihood that an ovarian mass is cancerous prior to surgery would accurately identify more women with ovarian cancer if the... 
Printer Friendly Version
05/11/11Quest Diagnostics Announces Completion of Final Extension of the Subsequent Offering Period and Intent to Exercise Top-Up Option and Complete Merger
MADISON, N.J., May 11, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, and Spark Acquisition Corporation, its wholly owned subsidiary ("Spark"), announced today the completion of the final extension of the subsequent offering period with respect to Spark's cash tender offer for all outstanding shares of common stock of Celera Corporation (NASDAQ: CRA). The final extension of the subsequent o... 
Printer Friendly Version
05/11/11Quest Diagnostics to Speak at the Bank of America Merrill Lynch 2011 Healthcare Conference
MADISON, N.J., May 11, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Bank of America Merrill Lynch 2011 Healthcare Conference in Las Vegas. The presentation is scheduled for Thursday, May 12, 2011 at 12:50 p.m. Eastern Time. During the conference, the company will reaffirm its adjusted 2011 outlook before future special items. The company ... 
Printer Friendly Version
05/09/11Quest Diagnostics Sponsors American Cancer Society's Choose You® Movement
National Sponsor of Society Initiative to Prevent Cancer-Related Deaths MADISON, N.J., May 9, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics, the world's leading provider of diagnostic testing, information and services (NYSE: DGX), today announced its national sponsorship of Choose You®, the American Cancer Society's movement that inspires women to stay well by putting their health first and making healthy lifestyle choices to help prevent cancer. According to the American Cancer Society, 1... 
Printer Friendly Version
05/09/11Quest Diagnostics Announces Final Extension of Subsequent Offering Period for Shares of Celera
Offer Concludes at 5 p.m. Tomorrow, Tuesday, May 10th MADISON, N.J., May 9, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that Spark Acquisition Corporation, its wholly owned subsidiary ("Spark"), has extended the cash tender offer for all outstanding shares of common stock of Celera Corporation (NASDAQ: CRA).  The expiration date of the subsequent offering period has been ext... 
Printer Friendly Version
05/09/11Quest Diagnostics Reaches Agreement in Principle to Settle California Lawsuit Related to Medi-Cal Billing
MADISON, N.J., May 9, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced it has reached an agreement in principle to settle a previously disclosed civil lawsuit, brought by a California competitor, in which the State of California intervened. In the lawsuit, the plaintiffs alleged, among other things, that the company did not comply with California's "comparable charge" regulations, resulting in overpayments for laboratory testing services by Medi-Cal, Cal... 
Printer Friendly Version
05/06/11Quest Diagnostics Care360 EHR Customer Successfully Completes Meaningful Use Attestation to Receive the Medicare EHR Incentive
MADISON, N.J., May 6, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics® (NYSE: DGX) today announced that Care360 user Paulo Andre, M.D., a neurologist in Framingham, MA, was the first Care360 EHR customer to successfully complete the attestation process for demonstrating Meaningful Use of an electronic health record with an ONC-ATCB certified complete EHR* in accordance with the Centers for Medicare and Medicaid Services (CMS) EHR incentive program. Dr. Andre was the 25th physician in the U... 
Printer Friendly Version
05/05/11Quest Diagnostics Launches Simplexa(TM) C. Difficile Universal Direct Test in Europe
First test from the Focus Diagnostics' Simplexa product line for the hospital-acquired infection (HAI) market MADISON, N.J. and CYPRESS, Calif., May 5, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the availability in Europe of the Simplexa C. difficile Universal Direct test on the 3M(TM) Integrated Cycler. The new CE marked in vitro diagnostic (IVD) Simplexa test enable... 
Printer Friendly Version
05/04/11Quest Diagnostics Announces Successful Tender Offer and Commencement of a Subsequent Offering Period for Shares of Celera
MADISON, N.J., May 4, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that Spark Acquisition Corporation, its wholly owned subsidiary ("Spark"), successfully completed the cash tender offer for all outstanding shares of common stock of Celera Corporation (NASDAQ: CRA), which expired at 5:00 p.m., New York City time, on Tuesday, May 3, 2011. Computershare Trust Company, N.A.,... 
Printer Friendly Version
05/03/11Quest Diagnostics Announces One Day Extension of Offer to Acquire Celera to 5pm Today
Over 52% of Fully-Diluted Shares Tendered to Date, Including Guaranteed Shares MADISON, N.J., May 3, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that Spark Acquisition Corporation, its wholly owned subsidiary ("Spark"), has extended the expiration of its tender offer to acquire all outstanding shares of common stock of Celera Corporation (NASDAQ: CRA) for $8.00 per shar... 
Printer Friendly Version
05/03/11Quest Diagnostics to Speak at the Deutsche Bank 36th Annual Healthcare Conference
MADISON, N.J., May 3, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Deutsche Bank 36th Annual Healthcare Conference in Boston. The presentation is scheduled for Wednesday, May 4, 2011 at 10:40 a.m. Eastern Time. During the conference, the company will reaffirm its adjusted 2011 outlook before future special items. The company expects reven... 
Printer Friendly Version
04/28/11Quest Diagnostics CE Marks Simplexa(TM) Tests for Epstein Barr and BK Viruses for Sale in Europe
Focus Diagnostics' Simplexa molecular tests on the 3M(TM) Integrated Cycler aid in detecting infectious disease viruses for organ transplant and other immunocompromised patients MADISON, N.J., and CYPRESS, Calif., April 28, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that two new Simplexa-branded molecular test kits developed by its Focus Diagnostics business have been ... 
Printer Friendly Version
04/20/11Quest Diagnostics Reports First Quarter 2011 Financial Results
- Total revenues of $1.8 billion, up 1% - Adjusted diluted earnings per share of $1.00 - Reported diluted earnings per share of $0.86 MADISON, N.J., April 20, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that for the first quarter ended March 31, 2011, adjusted income from continuing operations was $164 million, or $1.00 per diluted share, compared to $182 million, or $0.99 ... 
Printer Friendly Version
04/18/11Quest Diagnostics Launches Hepatitis C Virus Therapy Test Based on IL28B Gene Variants
AccuType(R) IL28B test now available to physicians and for clinical trials research MADISON, N.J., April 18, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the availability of its AccuType(R) IL28B test for aiding in the prediction of patient response to peginterferon alpha-based therapy for hepatitis C virus (HCV) infection. Quest Diagnostics is now offering the test to p... 
Printer Friendly Version
04/18/11Quest Diagnostics Extends Tender Offer for all Outstanding Shares of Celera Corporation to May 2, 2011
Enters into Memorandum of Understanding Providing for the Settlement of Merger Agreement Litigation MADISON, N.J., April 18, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostics testing, information and services, announced today that, in connection with the entry by it and Celera Corporation (NASDAQ: CRA) into a memorandum of understanding (the "MOU") providing for the settlement of previously consolidated purported class actio... 
Printer Friendly Version
04/13/11Quest Diagnostics Announces HSR Clearance for the Acquisition of Celera
MADISON, N.J., April 13, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired in connection with the $8 per share all cash tender offer by its wholly-owned subsidiary, Spark Acquisition Corporation, to purchase all outstanding shares of common stock of Celera Corporation (NASDAQ: CRA). Expiration of the waiting period under the HSR Act satisfi... 
Printer Friendly Version
04/12/11Quest Diagnostics to Release First Quarter 2011 Financial Results
MADISON, N.J., April 12, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report first-quarter 2011 results on Wednesday, April 20, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the conference call through a live audio webcast available on Q... 
Printer Friendly Version
04/06/11Quest Diagnostics Honored for Diagnostic Innovation at 2011 Edison Awards
Simplexa(TM) molecular diagnostic test on the 3M(TM) Integrated Cycler wins bronze for best new product, science and medical diagnostic MADISON, N.J., April 6, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa(TM) molecular test on the 3M(TM) Integrated Cycler was honored with a bronze award for best new science and medical diagnostic product during the 2011... 
Printer Friendly Version
04/04/11Quest Diagnostics Completes Acquisition of Athena Diagnostics
Solidifies leadership in growing market for neurology diagnostics MADISON, N.J., April 4, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced it has completed its previously announced acquisition of Athena Diagnostics, an esoteric laboratory specializing in genetic testing for neurological disorders, from Thermo Fisher Scientific (NYSE: TMO). Athena Diagnostics will contin... 
Printer Friendly Version
03/28/11Quest Diagnostics Commences Tender Offer for Acquisition of Celera
MADISON, N.J., March 28, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today it has commenced a tender offer through its wholly owned subsidiary, Spark Acquisition Corporation, for all of the outstanding shares of common stock (the "Shares") of Celera Corporation (Nasdaq: CRA), one of the world's pioneers in genetic diagnostics discovery and development for $8.00 per share in cash... 
Printer Friendly Version
03/22/11Quest Diagnostics Launches National Electronic Health Records Awareness Tour Showcasing Care360 EHR
Small Practice Physicians Can Learn About the Benefits of EHR Adoption During 12-Week Care360 EHR Road Test Tour MADISON, N.J., March 22, 2011 /PRNewswire via COMTEX/ -- Later this month, Quest Diagnostics (NYSE: DGX) will demonstrate how physicians can benefit from $39 billion in federal incentives by utilizing Care360(TM) EHR. The 12-week, 10-city Care360 EHR Road Test tour was developed to help hospitals and physician practices across the nation experience first-hand the operational and fi... 
Printer Friendly Version
03/21/11Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
MADISON, N.J., March 21, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (the "Company") (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it intends to offer $1,250,000,000 in aggregate principal amount of four series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions. The notes will be fully and uncon... 
Printer Friendly Version
03/18/11Quest Diagnostics to Acquire Celera, Strengthening Position as World's Leading Innovator in Molecular Diagnostics and Development
-- Provides Immediate Access to Proprietary Genetic Tests and Pipeline of Biomarkers to Drive Sustainable Growth -- -- Berkeley HeartLab Brings Unique Esoteric Cardiovascular Test Offering and Specialized Sales Force -- -- Adds Leading Genetic IVD Products and Development Capability -- -- Transaction Valued at Approximately $344 Million, Net of Acquired Cash and Short-Term Investments -- MADISON, N.J. and ALAMEDA, Calif., March 18, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorpor... 
Printer Friendly Version
03/17/11New York State Approves the Quest Diagnostics ColoVantage(TM) Colorectal Cancer Blood Test
Test designed to promote colorectal cancer evaluation of the nearly 53 million patients in the U.S. who resist recommended screening MADISON, N.J., March 17, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading cancer diagnostics company, today announced that its ColoVantage test has been approved by New York State's Department of Health for testing onsamples of patients in the state. It is believed to be the first molecular colorectal cancer detectio... 
Printer Friendly Version
03/14/11Quest Diagnostics to Speak at the Barclays Capital 2011 Global Healthcare Conference
MADISON, N.J., March 14, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Barclays Capital 2011 Global Healthcare Conference in Miami. The presentation is scheduled for Tuesday, March 15, 2011 at 9:00 a.m. Eastern Time. During the conference, the company will reaffirm its 2011 guidance. Excluding the impact of the acquisition of Athena Diagno... 
Printer Friendly Version
03/04/11Quest Diagnostics Ranked Among FORTUNE Magazine's 'World's Most Admired Companies' for Fourth Consecutive Year
MADISON, N.J., March 4, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that it has been included on FORTUNE magazine's "World's Most Admired Companies" list. Quest Diagnostics moved to second in the "Health Care" industry category of "Pharmacy and Other Services." The 2011 ranking is the fourth consecutive year that the company has been included on FORTUNE magazine's we... 
Printer Friendly Version
02/28/11Quest Diagnostics to Speak at the Citi 2011 Global Healthcare Conference
MADISON, N.J., Feb. 28, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Citi 2011 Global Healthcare Conference in New York City. The presentation is scheduled for Wednesday, March 2, 2011 at 11:30 a.m. Eastern Time. During the conference, the company will reaffirm its 2011 guidance. The company expects revenues to grow approximately 1%, oper... 
Printer Friendly Version
02/24/11Quest Diagnostics to Acquire Athena Diagnostics, Establishing Leading Position in Rapidly Growing Neurology Testing Market
Addition of Premier Provider of Neurology Testing to Complement Quest Diagnostics' Leadership in Testing for Cancer, Infectious Disease and Cardiovascular Disease -- MADISON, N.J., Feb. 24, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it has signed a definitive agreement to acquire Athena Diagnostics, an esoteric laboratory specializing in genetic testing for neurol... 
Printer Friendly Version
02/22/11Quest Diagnostics Care360(TM) Becomes First Certified, Commercially Available EHR to Include Direct Project Specifications
Enhancements to Care360(TM) EHR Provide Physicians with the Ability to Securely Share Patient Information Across Disparate Systems ORLANDO, Fla., Feb. 22, 2011 /PRNewswire via COMTEX/ -- HIMSS 2011 -- At HIMSS 2011 in Orlando, Florida, Quest Diagnostics (NYSE: DGX) announcedthe availability of the next release of its Care360(TM) Electronic Health Record (EHR) solution, which is the first certified, commercially available EHR to include the Direct Project specifications established under the c... 
Printer Friendly Version
02/16/11Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Feb. 16, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on April 19, 2011, to shareholders of record of Quest Diagnostics common stock on April 5, 2011. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information and ... 
Printer Friendly Version
02/10/11Quest Diagnostics and Withings Announce Availability of Integrated WiFi Weight Tracking for the Gazelle Mobile Health Platform
MADISON, N.J., Feb. 10, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics and Withings announced that the Withings WiFi Body Scale, the world's first WiFi connected personal weight scale, can now automatically import body weight data directly into Gazelle(TM), the secure mobile health platform from Quest Diagnostics. With Gazelle, users can electronically receive their Quest Diagnostics laboratory results and manage their personal health information directly from their Apple(R) iPhone, BlackBer... 
Printer Friendly Version
02/02/11Quest Diagnostics to Speak at the UBS Global Healthcare Services Conference 2011
MADISON, N.J., Feb. 2, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the UBS Global Healthcare Services Conference 2011 in New York City. The presentation is scheduled for Tuesday, February 8, 2011 at 8:30 a.m. Eastern Time. During the conference, the company will reaffirm its 2011 guidance. The company expects revenues to grow approximately 1... 
Printer Friendly Version
02/01/11Quest Diagnostics Announces Pricing in Offering of Common Stock by the Company's Largest Shareholder
MADISON, N.J., Feb. 1, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced the pricing of the previously announced secondary public offering of 15,377,600 shares of Quest Diagnostics common stock held by its largest stockholder, SB Holdings Capital Inc., an affiliate of GlaxoSmithKline plc ("GSK") at a price to the public of $56.25. Quest Diagnostics has not sold any shares of common stock in the offering and will not receive any of the proceeds from th... 
Printer Friendly Version
01/31/11/C O R R E C T I O N -- Quest Diagnostics Incorporated/
MADISON, N.J., Jan. 31, 2011 /PRNewswire via COMTEX/ --In the news release, Quest Diagnostics Announces Offering of Common Stock by the Company's Largest Stockholder, issued 31-Jan-2011 by Quest Diagnostics Incorporated over PR Newswire, we are advised by the company that the third paragraph should read, "Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC are joint bookrunners for the offering" rather than, "Deutsche Bank Securities Inc. will act as lead manager for the offering, and J... 
Printer Friendly Version
01/31/11Quest Diagnostics Agrees to Repurchase 15.4 Million Shares From Largest Shareholder
MADISON, N.J., Jan. 31, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX) today announced that it had agreed to repurchase at a negotiated price 15.4 million shares of its common stock from its largest shareholder, an affiliate of GlaxoSmithKline plc (GSK). Subsequent to the transaction, GSK will no longer hold any shares of common stock of Quest Diagnostics. "Through this transaction, we are taking advantage of a unique opportunity to enhance shareholder value and d... 
Printer Friendly Version
01/31/11Quest Diagnostics Announces Offering of Common Stock by the Company's Largest Stockholder
MADISON, N.J., Jan. 31, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX) today announced the underwritten public offering of 15,377,600 shares of Quest Diagnostics common stock held by its largest stockholder, SB Holdings Capital Inc., an affiliate of GlaxoSmithKline plc ("GSK"). After giving effect tothe proposed offering andthe company's repurchase from GSK of15,377,551 shares of Quest Diagnostics common stock also announced today, it isexpected that GSK will no longer... 
Printer Friendly Version
01/25/11Quest Diagnostics Reports Fourth Quarter 2010 Financial Results; Provides Guidance for 2011
- Diluted EPS of $0.97, unchanged from 2009 - Revenues of $1.8 billion, 1.3% below 2009 - Cash flow from operations of $340 million - 2011 guidance before special items: Diluted EPS between $4.10 and $4.30; revenues to grow approximately 1% - Board approves $750 million share repurchase authorization, bringing total available to $1 billion MADISON, N.J., Jan. 25, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing,... 
Printer Friendly Version
01/25/11Quest Diagnostics Increases Share Repurchase Authority by $750 Million
Increase brings current authorization to $1 billion -- MADISON, N.J., Jan. 25, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that its Board of Directors increased the company's share repurchase authorization by $750 million. This action increases the current share repurchase authorization to $1 billion. During 2010, the company repurchased approximately 15 million shares of... 
Printer Friendly Version
01/25/11Oral Fluid Reveals More Heroin Use Than Previously Believed, According to Quest Diagnostics Drug Testing Index
MADISON, N.J., Jan. 25, 2011 /PRNewswire via COMTEX/ --Oral fluid has revealed approximately five times more heroin use in the general U.S. workforce than previously believed, according to new data today released by Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services. In the company's first special report on oral fluid testing with more than 320,000 oral-fluid samples from the general U.S. workforce from January to June 2010, d... 
Printer Friendly Version
01/13/11Quest Diagnostics to Release Fourth Quarter and Full Year 2010 Financial Results
MADISON, N.J., Jan. 13, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report fourth quarter and full year 2010 results and provide financial guidance for 2011 on Tuesday, January 25, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the confe... 
Printer Friendly Version